A glycosylated Fc‐fused glucagon‐like peptide‐1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide

AIM: To evaluate the pharmacokinetic and pharmacodynamic properties of a novel glycosylated Fc‐fused glucagon‐like peptide‐1(GLP‐1‐gFc) receptor agonist with distinctive receptor binding affinity, designed to improve in vivo stability and safety relative to the commercial GLP‐1 analogue dulaglutide,...

Descripción completa

Detalles Bibliográficos
Autores principales: An, In Bok, Byun, Mi Sun, Yang, Sang In, Choi, Yuri, Woo, Jung Won, Jang, Hak Chul, Sung, Young Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383507/
https://www.ncbi.nlm.nih.gov/pubmed/32314505
http://dx.doi.org/10.1111/dom.14058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383507/
https://www.ncbi.nlm.nih.gov/pubmed/32314505
http://dx.doi.org/10.1111/dom.14058

Ejemplares similares